Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

(Reuters) - Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).